生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139 生物科技

休市中 05-29 16:00:00 EDT

1,132.89

-2.41

-0.21%

最高1,137.22	最低1,127.79	成交量9.37亿
今开1,135.28	昨收1,135.29	日振幅0.83%
总市值0.00	流通市值0.00	总股本0.00
成交额218.24亿	换手率--	流通股本0.00
市净率6.891282	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1132.8872,"timestamp":1780084799999,"preClose":1135.2926,"halted":0,"volume":936615770,"delay":0,"changeRate":-0.002119,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-2.405396,"latestTime":"05-29 16:00:00 EDT","open":1135.2808,"high":1137.2172,"low":1127.7914,"amount":21823922184.94382,"amplitude":0.008303,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.891282,"peRate":-149.672835,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"1105034196","title":"Mirum Pharmaceuticals在欧洲肝病研究学会国际肝病大会上公布罕见肝病项目新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1105034196","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105034196?lang=zh_cn&edition=full","pubTime":"2026-05-31 00:00","pubTimestamp":1780156813,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. (MIRM) 宣布，其针对罕见肝病的研究项目所取得的最新数据，已在2026年欧洲肝病研究学会（EASL）国际肝病大会上正式公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109149162","title":"Mineralys Therapeutics：Lorundrostat在3期Launch-Htn试验中显著降低慢性肾病患者血压","url":"https://stock-news.laohu8.com/highlight/detail?id=1109149162","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109149162?lang=zh_cn&edition=full","pubTime":"2026-05-30 23:15","pubTimestamp":1780154117,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. 宣布，其在研药物Lorundrostat于针对慢性肾病合并高血压患者的3期Launch-Htn临床试验中，展现出显著的血压降低效果。该试验数据为Lorundrostat在控制这一患者群体血压方面的潜力提供了有力支持。Lorundrostat作为一种新型治疗选择，其积极的3期结果可能为患者带来新的希望。公司表示，详细的试验数据将在未来的医学会议上公布，并计划与监管机构讨论后续的申报路径。这一进展对Mineralys Therapeutics, Inc.而言是一个重要的里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198381190","title":"Mineralys Therapeutics试验显示：Lorundrostat显著降低尿白蛋白与肌酐比值","url":"https://stock-news.laohu8.com/highlight/detail?id=1198381190","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198381190?lang=zh_cn&edition=full","pubTime":"2026-05-30 23:15","pubTimestamp":1780154115,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. 公布的一项试验数据显示，其候选药物Lorundrostat在降低尿白蛋白与肌酐比值（UACR）方面取得了显著成效。这一关键生物标志物的改善，对于评估肾脏健康，特别是在高血压相关肾损伤领域，具有重要的临床意义。试验结果进一步支持了该药物在靶向治疗中的潜在价值，为后续开发提供了积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123865097","title":"Mineralys Therapeutics在ESH 2026会议上公布Lorundrostat针对高血压合并慢性肾病患者的3期LAUNCH-HTN试验新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1123865097","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123865097?lang=zh_cn&edition=full","pubTime":"2026-05-30 23:15","pubTimestamp":1780154115,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics公司在2026年欧洲高血压与心血管保护会议（ESH 2026）上，公布了其候选药物lorundrostat针对高血压合并慢性肾病患者的三期LAUNCH-HTN临床试验的新数据。这项关键研究旨在评估该药物在这一患者群体中的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113856617","title":"Mineralys Therapeutics：Lorundrostat在伴或不伴慢性肾病的参与者中展现为期12周的优良安全性特征","url":"https://stock-news.laohu8.com/highlight/detail?id=1113856617","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113856617?lang=zh_cn&edition=full","pubTime":"2026-05-30 23:15","pubTimestamp":1780154112,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics公司宣布，其研究性药物Lorundrostat在为期12周的临床试验中，于伴有或不伴有慢性肾病的参与者群体内均表现出良好的安全性特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163935567","title":"伊克力西斯：Cabometyx在非功能性神经内分泌肿瘤中降低进展或死亡风险74%，在功能性肿瘤中降低60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163935567","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163935567?lang=zh_cn&edition=full","pubTime":"2026-05-30 22:04","pubTimestamp":1780149862,"startTime":"0","endTime":"0","summary":"伊克力西斯（Exelixis）宣布，其药物卡博替尼（Cabometyx）在治疗神经内分泌肿瘤方面取得了积极成果。数据显示，该药物在非功能性神经内分泌肿瘤患者中，将疾病进展或死亡的风险显著降低了74%。同时，在功能性神经内分泌肿瘤患者群体中，这一风险降低幅度也达到了60%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL","BK4532","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151042498","title":"Immunome公司Varegacestat疗法在主要及所有关键次要疗效终点上均显示出统计学显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1151042498","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151042498?lang=zh_cn&edition=full","pubTime":"2026-05-30 20:13","pubTimestamp":1780143195,"startTime":"0","endTime":"0","summary":"Immunome公司宣布，其药物Varegacestat在临床试验中取得了积极成果。数据显示，该疗法不仅在主要疗效终点上实现了统计学意义的显著改善，而且在所有预先设定的关键次要疗效终点上也同样观察到了具有统计学意义的积极变化。这一结果标志着该候选药物在相关治疗领域取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189204083","title":"Replimune Group：Rp1联合纳武利尤单抗在抗PD-1治疗失败的黑色素瘤患者中实现32.9个月中位总生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1189204083","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189204083?lang=zh_cn&edition=full","pubTime":"2026-05-30 20:11","pubTimestamp":1780143081,"startTime":"0","endTime":"0","summary":"Replimune Group Inc.公布其候选疗法Rp1联合纳武利尤单抗的最新数据，在对抗PD-1疗法已产生耐药性的晚期黑色素瘤患者群体中，展现出令人瞩目的长期生存获益，中位总生存期达到32.9个月。这一结果凸显了该联合疗法为这类难治性患者提供潜在新治疗选择的临床价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130944112","title":"Veracyte与Enzamet试验揭示：Decipher前列腺检测可识别转移性前列腺癌化疗获益患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1130944112","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130944112?lang=zh_cn&edition=full","pubTime":"2026-05-30 20:11","pubTimestamp":1780143080,"startTime":"0","endTime":"0","summary":"Veracyte公司宣布，其与Enzamet试验合作获得的数据显示，Decipher前列腺基因组分类检测能够有效识别出哪些转移性前列腺癌患者可能从化疗中获益。这一发现为临床精准治疗决策提供了重要依据，有望帮助医生更准确地筛选适合接受强化化疗的患者群体，从而优化治疗策略并改善患者预后。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VCYT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144835206","title":"因塞特医疗：关键Frontmind试验显示Tafasitamab联合疗法显著延长无进展生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1144835206","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144835206?lang=zh_cn&edition=full","pubTime":"2026-05-30 20:08","pubTimestamp":1780142897,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，其关键的Frontmind临床试验数据表明，Tafasitamab（商品名Monjuvi®/Minjuvi®）联合治疗方案能够显著延长患者的无进展生存期。这一积极结果凸显了该疗法在相关治疗领域的潜在价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4550","BK4585","BK4532","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155329065","title":"Cogent Biosciences联合疗法在GIST患者中展现统计学显著无进展生存期优势","url":"https://stock-news.laohu8.com/highlight/detail?id=1155329065","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155329065?lang=zh_cn&edition=full","pubTime":"2026-05-30 20:07","pubTimestamp":1780142856,"startTime":"0","endTime":"0","summary":"Cogent Biosciences公司宣布，其药物Bezuclastinib的联合疗法在胃肠道间质瘤（GIST）患者中取得了统计学上显著的无进展生存期（PFS）优势。这一积极数据为该公司针对这一难治性癌症的研发管线带来了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157043128","title":"Cogent Biosciences 公布PEAK III期试验详细临床数据：Bezuclastinib联合舒尼替尼治疗胃肠道间质瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1157043128","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157043128?lang=zh_cn&edition=full","pubTime":"2026-05-30 20:01","pubTimestamp":1780142467,"startTime":"0","endTime":"0","summary":"Cogent Biosciences 公司在2026年美国临床肿瘤学会年会上，公布了其PEAK III期试验的详细临床数据。该试验评估了Bezuclastinib与舒尼替尼联合疗法，用于治疗胃肠道间质瘤患者的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","COGT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104190016","title":"GRAIL在2026年ASCO年会上公布NHS-Galleri试验完整结果，显示晚期癌症诊断数量显著减少","url":"https://stock-news.laohu8.com/highlight/detail?id=1104190016","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104190016?lang=zh_cn&edition=full","pubTime":"2026-05-30 20:01","pubTimestamp":1780142464,"startTime":"0","endTime":"0","summary":"GRAIL公司在2026年美国临床肿瘤学会（ASCO）年会上，正式公布了其NHS-Galleri试验的完整数据。该试验结果明确显示，通过其多癌种早期检测血液检测技术Galleri，能够显著降低第四期（晚期）癌症的诊断数量。这一关键数据进一步验证了该检测方法在癌症早期发现与干预方面的潜在价值，为改善癌症患者预后提供了新的有力证据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639609318","title":"关键NGS证终止注册，遭遇利好真空期的燃石医学(BNR.US)股价5日跌超40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639609318","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639609318?lang=zh_cn&edition=full","pubTime":"2026-05-30 19:40","pubTimestamp":1780141250,"startTime":"0","endTime":"0","summary":"5月25日，国家药监局更新了医疗器械注册状态，其中显示，燃石医学申报的人循环肿瘤DNA多基因突变联合检测试剂盒已“终止注册”。在随后的5月22日，燃石医学股价大幅收跌11.09%，并由此开启了一段急速下跌过程。如今，已获进入优先审批通道的肺癌NGS血检证宣布“终止注册”，在短期内对燃石医学股价的负面影响较大，因为在2026中报披露之前，肺癌NGS血检证的获批下证是今年上半年公司股价的关键催化剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448145.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4179","NGS","BK4139","BNR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1112660145","title":"WhiteHawk Therapeutics提交SEC文件 现有股东拟发售及转售至多2232万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1112660145","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112660145?lang=zh_cn&edition=full","pubTime":"2026-05-30 04:19","pubTimestamp":1780085958,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，生物技术公司WhiteHawk Therapeutics已登记由售股股东发售及转售最多2232万股普通股。此举意味着现有股东可能在未来一段时间内，根据市场情况逐步出售其持有的公司股份。此类备案通常为后续的股票销售铺平道路，但具体出售的时间、价格和数量将由股东自行决定。市场参与者将密切关注此举可能对股票流动性和股价产生的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","WHWK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178148202","title":"Climb Bio提交SEC文件：现有股东拟转售最多1160万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1178148202","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178148202?lang=zh_cn&edition=full","pubTime":"2026-05-30 04:08","pubTimestamp":1780085294,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件显示，Climb Bio Inc. 已登记由售股股东进行的普通股转售，涉及股份数量最高可达1160万股。此次提交意味着相关股东已获得在未来公开市场出售这部分股份的资格，但具体出售的时间、价格及数量将由股东自行决定。公司本身不会从此次售股中获得任何收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLYM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639725276","title":"BMS多发性骨髓瘤III期数据亮眼 C4 Therapeutics受提振大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2639725276","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639725276?lang=zh_cn&edition=full","pubTime":"2026-05-30 03:49","pubTimestamp":1780084140,"startTime":"0","endTime":"0","summary":"百时美施贵宝日前公布了其在研药物美齐格米德的III期临床试验阳性数据。结果显示，该联合疗法将复发或难治性多发性骨髓瘤患者的疾病进展或死亡风险降低了52%。这一积极结果不仅推高了施贵宝的股价，也显著提振了同领域生物科技公司C4 Therapeutics的市场表现。　　在施贵宝宣布这一消息后，C4 Therapeutics股价应声大涨，盘中一度触及52周新高，最终收涨逾19%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-30/doc-inhzrera0552232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","BMS","LENZ","BK4539","III","BK4007","BK4139","CCCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188903553","title":"Veracyte - Optima试验显示Prosigna检测可识别高风险乳腺癌患者，使其免于化疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1188903553","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188903553?lang=zh_cn&edition=full","pubTime":"2026-05-30 03:17","pubTimestamp":1780082235,"startTime":"0","endTime":"0","summary":"Veracyte公司宣布，其Optima试验结果表明，Prosigna检测能够有效识别出高风险乳腺癌患者中那些可以安全避免化疗的个体。这一发现为精准医疗在乳腺癌治疗领域的应用提供了有力支持，有望帮助更多患者减少不必要的治疗负担。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143603220","title":"曼恩凯德生物医疗宣布FDA批准Afrezza®，首个且唯一用于6岁及以上糖尿病儿童及青少年的吸入式餐时胰岛素","url":"https://stock-news.laohu8.com/highlight/detail?id=1143603220","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143603220?lang=zh_cn&edition=full","pubTime":"2026-05-30 00:30","pubTimestamp":1780072234,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗宣布，其产品Afrezza®已获得美国食品药品监督管理局的批准。该药物成为首个且唯一获批用于6岁及以上糖尿病儿童及青少年群体的吸入式餐时胰岛素。这一里程碑式的批准为这一特定年龄段的患者提供了一种全新的胰岛素给药方式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4139","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156020992","title":"辉瑞与BioNTech新冠疫苗获授权，将为6个月至11岁儿童统一使用10微克剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=1156020992","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156020992?lang=zh_cn&edition=full","pubTime":"2026-05-29 23:47","pubTimestamp":1780069665,"startTime":"0","endTime":"0","summary":"辉瑞公司与其合作伙伴BioNTech SE共同研发的新冠疫苗已获得授权，将面向6个月至11岁的所有儿童群体，统一采用10微克的剂量进行接种。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","IE00B3T34201.USD","IE0002270589.USD","LU0225284248.USD","IE00B19Z3B42.SGD","LU1894683348.USD","BK4551","BK4592","IE000M9KFDE8.USD","SG9999001176.SGD","SG9999001176.USD","LU0289739699.SGD","BK4588","LU1057294990.SGD","LU1066051498.USD","SG9999002232.USD","LU1023059063.AUD","BNTX","LU0225771236.USD","LU0234572021.USD","BK4007","BK4599","SG9999011175.SGD","SG9999002224.SGD","LU0306806265.USD","LU0985481810.HKD","LU0122379950.USD","BK4535","LU0321505868.SGD","LU0456855351.SGD","IE00BBT3K403.USD","LU0306807586.USD","BK4533","LU1066053197.SGD","BK4139","IE00BLSP4239.USD","IE00B19Z3581.USD","LU0170899867.USD","LU0321505439.SGD","LU1883839398.USD","LU0058720904.USD","BK4550","IE00BLSP4452.SGD","LU1894683264.USD","LU0868494617.USD","BK4548","SG9999003800.SGD","BK4581","BK4585","SG9999013999.USD","PFE","BK4568","SGXZ57979304.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}